Clinical Trial Update: Study of Therapeutic Options for Subjects Discontinuing Efalizumab and Experiencing Disease Recurrence [Phase 4]

View source ↗

Summary

This Phase 4 clinical trial evaluated therapeutic options for psoriasis patients who discontinued efalizumab and experienced disease recurrence.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Psoriasis | Phase 4 | Status: COMPLETED | Results posted: 2010-05-11